Research Article
Profiling of Somatic Mutations in Phaeochromocytoma and Paraganglioma by Targeted Next Generation Sequencing Analysis
Table 2
Oncogene mutations identified in next generation sequencing analysis of 85 PCC/PGL/HNPGL.
| Tumour ID | Clinical diagnosis | Type of tumour | Gene | Codon change | Aminoacid change | Allele frequency |
| P19 | Phaeochromocytoma | PCC | HRAS | c.37G>C | G13R | 72% | P20 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 36% | P21 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 27% | P22 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 40% | P23 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 50% | P24 | Phaeochromocytoma | PCC | HRAS | c.182A>G | Q61R | 26% | P25 | Phaeochromocytoma | PCC | BRAF | c.1799T>A | V600E | 10% | P26 | Phaeochromocytoma | PCC | TP53 | c.1010G>A | R337H | 4% | P27 | Phaeochromocytoma | PCC | TP53 | c.1010G>A | R337H | 21% |
|
|